No Data
No Data
Investors Don't See Light At End Of ChemPartner PharmaTech Co.,Ltd.'s (SZSE:300149) Tunnel
ChemPartner Pharmatech (300149.SZ): Currently, its wholly-owned subsidiary Hongyuan Pukang sells probiotics and probiotic products.
ChemPartner Pharmatech (300149.SZ) stated on its investor interaction platform on July 26 that the company's main business is pharmaceutical research and development and production services (CRO/CDMO), providing chemical and biological drug research and development and production services to global pharmaceutical companies, biotechnology companies and research institutions. According to the company's development strategy to focus on medical research and development and production service business (CRO/CDMO business), the company sold its probiotics (including fructo-oligosaccharides) business to the public in June 2022. Currently, its wholly-owned subsidiary, Hongyuan Pukang, sells probiotics and probiotic products.
ChemPartner Pharmatech (300149.SZ): As of June 4, the company had 24,470 shareholders.
ChemPartner Pharmatech (300149.SZ) stated on the investor interaction platform on June 6th that as of June 4th, the number of shareholders in the company was 24,470.
Chempartner Pharmatech (300149.SZ) owns a fully integrated R&D and production service platform covering chemical drugs and biologics.
On June 4th, Gelon Hui reported that Chempartner Pharmatech (300149.SZ) has over 20 years of development and accumulation, and has competitive advantages in core technology, innovation ability, customer base, and project experience. 1. The company has a fully integrated research and development and production service platform covering the entire process of chemical medicine and biological medicine, and the service content includes chemical medicine research and development, biological medicine research and development, ADC drug development, biopharmaceutical and pharmacological efficacy, drug metabolism kinetics and early toxicity, and large molecule drug process development and production. Especially for ADC coupling drug one-stop research and development platform, it has been in possession for 15 years.
Meta Bright, ChemPartner Pharmatech to Develop Biotechnology Hub in Malaysia; Shares Rally 6%
Wisdom Pharmaceuticals (300149.SZ): Currently there is no GLP certification
On May 27, Ge Longhui Pharmaceutical (300149.SZ) said on the investor interactive platform that the company currently does not have GLP certification. The company's bioanalysis center can provide bioanalytical services in accordance with FDA/NMPA GLP in pre-clinical and clinical research stages, and has obtained CNAS certification.
No Data